IntroDuctIon
The ability to stratify and distinguish disease mutations holds enormous potential for systems-level understanding of human cancer and for applications in precision medicine. With rapidly evolving next-generation sequencing platforms, over the past decade hundreds of thousands of human genome sequences have become available from patients stricken by many cancer types [1] [2] [3] [4] [5] [6] [7] . To evaluate the impact of such a deluge of genotypic information, it is critical to understand the functional and mechanistic molecular consequences of genotypic differences 8, 9 . Accumulating genotypic information in the absence of efficient and informative functional analyses has created a bottleneck in understanding of genotype-phenotype relationships in human cancer 10 (Fig. 1) . To this end, a number of deep mutagenesis technologies have emerged in recent years, including PFunkel 11 , deep mutational scanning 12, 13 , Clone-seq 14 , and, most recently, Gateway-mediated functional variomics 15 . These strategies are all coupled with next-generation sequencing. PFunkel uses Pfu DNA polymerase isolated from Pyrococcus furiosus and optimized conditions for PCR-based mutagenesis, and degrades wild-type sequences in the mutant library by adding uracil DNA glycosylase and exonuclease III. Deep mutational scanning constructs a short-sequence mutation library by Gibson assembly and ligation, followed by measurable functional assays. Clone-seq is another PCR-based mutagenesis platform using Phusion polymerase. By contrast, functional variomics integrates Gateway technology and barcoded sequencing to establish a high-throughput system that is markedly easier to design, is highly specific, and is well-suited for large-scale and multiplexed mutagenesis in a variety of cancer-related genes and pathways.
Understanding cancer heterogeneity by characterizing mutations at large scale Genetic heterogeneity underlies phenotypic diversity across cancer patient populations 16 . The Cancer Genome Atlas 17 , the Catalogue of Somatic Mutations in Cancer 18 , and the International Cancer Genome Consortium 19 sequencing projects have cataloged millions of rare and common cancer genomic variants. However, only a small fraction of these variants have been functionally characterized 20 . Age of disease onset, survival rate, drug response, and clinical pathology are more heterogeneous than originally anticipated in cancer patients [8] [9] [10] 20 . A critical challenge then is to identify causal disease variants 21 . In cancer, although germline and somatic variants have been identified in cancerassociated genes 22 , it is difficult to distinguish 'driver' mutations from the numerous 'passenger' mutations that accumulate during tumorigenesis. Even for a well-established cancer gene such as TP53, not all mutations are functionally equivalent 23 , and the molecular basis behind disease for most identified mutations remains elusive.
Pathogenic mutations in human cancer may exert different effects on cellular networks, ranging from loss of all the interactions of the gene ('quasi-null'), to specific perturbation of one or several but not all molecular interactions ('edgetic'), to retention of all wild-type interactions ('quasi-wildtype') 35, 36 . Systematic experimental efforts have just emerged to assess the extent to which network perturbations can account for disease phenotypes 37, 38 . Molecular interaction changes mediated by patientspecific mutations have been profiled to investigate on a large scale the underlying disease mechanisms 15, 39, 40 . By characterizing molecular interactions, the first version of a functional landscape for human disease mutations was charted 15 . For protein-protein interactions (PPIs) only, although common variants from healthy individuals rarely affect interactions, strikingly, ~30% of disease mutants exhibit selective perturbations of their wild-type interactions, whereas another ~30% result in loss of all interactions, probably because of defects in protein folding 15, 41 . Together, these results provide evidence for widespread mutation-induced interaction-specific network perturbations across a broad spectrum of diseases 15, 39 .
Here, we explain in detail how to use a Gateway-technologyintegrated, barcoded sequencing-based platform 15 to facilitate massively parallel site-directed mutagenesis at high efficiency and quality (Fig. 1) . We further describe functional assays to systematically dissect and stratify large numbers of cancer mutations, and to prioritize driver events. We include considerations for preparing error-free wild-type template sequences, protocols for rapid construction and verification of specific cancer mutations of interest, and finally the use of the resulting mutation entry clones for functional characterization and stratification in yeast cells and human embryonic kidney (HEK 293) cell lines. The system can similarly be applied to the generation and , and two mutation-specific internal forward and reverse primers are used. The two universal primers allow the preservation of the attB sites (green boxes) on both ends of the gene. The mutation-specific primers, MutF and MutR, encompassing the desired mutation, are designed to have an overlapping region of ~40 bp. The two DNA fragments flanking the mutation of a cancer gene are amplified using the primer pair AD-Tag1 and MutR, and the primer pair Term-Tag2 and MutF, respectively. For the fusion PCR, the two primary PCR products are fused together using the primer pair Tag1 and Tag2 (sequences shown in table 1) to generate the mutant allele. DNA fragments during the mutagenesis process are analyzed on 1% agarose E-Gels (96 samples). Fragment I, fragment II, and fusion PCR products are shown in a 96-well format (left, middle, and right, respectively). As is shown, fusion PCR products exhibit DNA sizes as an addition of the two fragment sizes.
High-resolution characterization. Most site-directed mutagenesis approaches do not have a functional stratification step for characterizing mutations, except for the deep mutational scanning platform 12 . However, this method cannot be applied to proteins with complex functions or no known functions. In marked contrast, the functional variomics platform can distinguish a large number of mutations at the fundamental molecular interaction level 45, 46 and at single-base resolution 36, 47 .
Limitations of the functional variomics system
Functional variomics is a robust site-directed mutagenesis pipeline that can efficiently construct a large library of (at least thousands) disease-specific mutations and experimentally dissect the functional role of each mutation. As the wild-type templates are from the ORFeome, it would not be possible to generate mutations in genes that are not available in the ORFeome. However, given the broad coverage and ever-expanding nature of the human ORFeome 45, 48 , this requirement does not severely limit the capability of functional variomics. Another possible limitation is the technical challenge of cloning mutations in high-GC content or low-complexity regions. This might lead to nonspecific off-target events, but optimization of primer design 49 could alleviate this issue.
Experimental design
High-throughput generation of human cancer mutation Gateway entry clones. Human cancer mutations can be cloned on a large scale using an enhanced high-throughput site-directed mutagenesis pipeline 15, 45 (Fig. 2) . First, the corresponding fulllength wild-type reference genes can be obtained from their entry clones in human ORFeome v8.1 (ref. 43 ). These wild-type entry clones can be transferred into the pDEST-AD vector (AD domain from the yeast transcription factor Gal4) to serve as a template for mutagenesis. This is followed by three PCR experiments. For a given cancer mutation, this process consists of two 'primary PCRs' to generate gene fragments flanking the mutation site and one 'fusion PCR' to obtain the full-length gene harboring the desired mutation. To create mutation entry clones, all the mutants can be cloned into the Gateway donor vector, pDONR223, by a BP ('attB × attP recombination' , where 'attB' stands for recombination attachment sites in bacteria and 'attP' stands for such sites in phage) reaction followed by bacterial transformation. Independent colonies for each mutant can be isolated for sequence confirmation.
Confirmation of mutations using barcoded next-generation sequencing.
To confirm expected mutations, mutant clones are PCR-amplified from each mutation entry clone colony (Fig. 3) . PCR products can be processed for next-generation sequencing 15, 45 . When multiple sets of mutations are being generated, distinct barcodes can be included for sequence verification (Fig. 3) . This makes it possible to combine multiple experiments in a single-sequencing run and separate them computationally afterward. For large-scale experiments, this approach is more cost-effective than traditional Sanger sequencing. Moreover, there is less loss of verified mutations due to failed sequencing, as each mutation PCR product is sequenced multiple times. The clones that have a full-length coverage with only the single desired mutation can be selected and consolidated.
Large-scale functional characterization of mutant clones. In recent years, large-scale functional variomics platforms have emerged to characterize mutant clones in a high-throughput manner. The HT-eY2H system is one of the most powerful functional approaches available to date for this purpose (Fig. 4) . HT-eY2H can be used to explore binary direct PPIs: it is cost-effective and can be applied on a proteome-wide scale. This system is based on the reconstitution of a functional transcription factor through the interaction between two proteins: one fused to the DNA-binding domain of the transcription factor (DB-X) and one fused to the activation domain (AD-Y) 50 . Several reporter genes can be used to detect an interaction between DB-X and AD-Y, including selectable, auxotrophic markers such as HIS3 (ref. 51 ). To accomplish this as stringently and efficiently as possible, an optimized protocol can be implemented to test each candidate interaction in replicate using high-stringency criteria to remove potential false positives 15, 45 . Finally, the identity of the clones exhibiting PPI phenotypes can be confirmed using next-generation sequencing 52 .
HT-eY2H system. Once available, the cancer mutant entry clones and their corresponding wild-type counterparts can be transferred by Gateway LR ('attL × attR recombination' , where 'L' = 'left' and 'R' = 'right') reactions into the HT-eY2H vectors, pDEST-DB and pDEST-AD, expressing the yeast Gal4 DNA-binding domain fusion proteins (DB-X) and activation domain fusion proteins (AD-Y). The DB-X and AD-Y plasmids can then be transformed into the haploid yeast Y8930, mating type MATα, with the genotype leu2-3,112 trp1-901 his3∆200 ura3-52 gal4∆ gal80∆ GAL2:: ADE2 GAL1::HIS3@LYS2 GAL7::lacZ@MET2cyh2 R , and selected on synthetic complete (SC) agar medium without leucine (SCLeu) to generate Y2H bait strains 51 . The prey strains expressing AD-Y can be transformed into the yeast Y8800, mating type MATa, with a genotype similar to that of Y8930, and selected on SC medium without tryptophan (SC-Trp) 45 .
PPI pairwise test. Individual DB-X and AD-Y yeast strains are inoculated into liquid cultures in SC-Leu and SC-Trp, respectively (Fig. 4) Validation of interaction network perturbations by GPCA in mammalian cells. Mutation-induced interaction perturbations can be validated with the high-throughput Gateway-compatible G. princeps protein-fragment complementation assay (GPCA) (Fig. 5) . The GPCA detects PPIs by fragment complementation of G. princeps luciferase 54 . pSPICA-C1 and pSPICA-N2 expression vectors each contain one of the two fragments of the humanized G. princeps luciferase (hGLuc F[1] and hGLuc F [2] , respectively) 54, 55 . The tested protein pairs can be transferred into the pSPICA-C1 and pSPICA-N2 vectors by LR-clonase-mediated Gateway reaction. As a result, the hGLuc F[1] luciferase fragment is linked to the C terminus of a tested protein, and the complementary hGLuc F [2] fragment is linked to the N terminus of a protein partner. Both mammalian expression vectors carry the same human cytomegalovirus promoter and are maintained as high copy number with the human virus SV40 replication origin.
Interaction scoring and data analysis. Protein pairs tested are defined as valid only if both partners are successfully cloned into expression vectors and both are transformed or transfected successfully into cells. The average interaction score of independent experimental repeats is considered to be the final interaction score for each protein pair. The protein pairs are tested together, with the positive-and negative-control pairs on the same experimental plates. A quantitative readout can be used to titrate the 'threshold' signal to an acceptable range. The threshold is defined so that any pair scoring above that threshold is considered 'positive' and otherwise is considered 'negative'. The threshold is set such that the false-positive recovery rate is as minimal as 1-2.5%. • This lysis buffer can be stored at −20 °C for months. SC dropout amino acid mixture SC dropout amino acid mixture is an amino acid mixture lacking leucine, tryptophan, and histidine. When necessary, leucine, tryptophan, or histidine, as well as the additives CHX and 3-AT, are added after autoclaving. The amino acid mixture can be generated by mixing equal amounts of the following components: alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, and valine. This mixture can be stored at room temperature for 1 year. SC stock solutions Prepare SC stock solutions using 100 mM histidine in H 2 O; 100 mM leucine in H 2 O; 40 mM tryptophan in H 2 O (store covered with aluminum foil at 4 °C); adenine (12 g/liter); 20 mM uracil in H 2 O; and 10 mg/ml CHX in ethanol (10,000× stock). These solutions can be stored at 4 °C for up to 6 months.
MaterIals

REAGENTS
• • table 1 | Primers for mutagenesis and sequence confirmation (with PROCEDURE step numbers at which they are required indicated in parentheses). proceDure large-scale computational design of cancer mutation cloning primers • tIMInG 1 d 1| For all mutation clones that must be created, design mutation-specific oligonucleotide primers (37-45 nt long) such that the first 18-22 nt correspond to the 5′ sequence flanking the mutation, then the mutation site, and the remaining 18-22 nt matching the 3′ flanking sequence. Corresponding sets of forward and reverse primer plates should be ordered (e.g., for a particular mutation, the forward primer is in plate 1 well A1, and the reverse primer is in plate 2 well A1). Wild-type primers are not necessary.  crItIcal step A decision often must be made on whether to include a stop codon in the primer or to have the vector provide the stop codon. The human ORFeome entry clones do not contain stop codons. This enables easy transfer into vectors harboring a C-terminal tag. However, if the destination vectors do not have a stop codon, then it is better to include a stop codon in the reverse primer.
primers for high-throughput mutagenesis
2| Dilute forward and reverse mutation-specific primers from
Step 1 in 96-well plates (e.g., PCR plates) to a final concentration of 1 µM each, in a volume of 100 µl of ddH 2 O.
preparation of mutagenesis pcr templates • tIMInG 3 d 3|
The human ORFeome contains a comprehensive collection of full-length wild-type entry clones. To prepare templates for PCR in our mutagenesis pipeline, we must transfer wild-type entry clones into the destination vector, pDEST-AD. Perform enzymatic digestion of the pDEST-AD vector as follows: 7| Pipette well to mix the master mix, and distribute 3 µl into each well of a 96-well plate. Add 2 µl of wild-type entry clone plasmids (50-100 ng/µl) per well. After a brief spin-down, incubate the plates at 25 °C for 4-12 h.
8| Thaw 1 ml of DH5α or DH10B bacterial competent cells on ice. Add 10 µl of cells to each well of a 96-well plate, and then add 1 µl of Gateway LR reaction products from Step 7 to each well of competent cells. Seal the plate with a heat sealer or aluminum foil, and incubate the plate on ice for 30 min.
9|
Heat-shock the plate at 42 °C in a standard thermocycler for 1 min, and incubate it on ice for 2 min.  crItIcal step Note that this step is not necessary if you are using Z-competent cells (Zymo Research, cat. no. T3020).
10| Add 40 µl of prewarmed (37 °C) SOC medium to each well. Seal the plate with a heat sealer or aluminum foil to avoid contamination. Then incubate the plate at 37 °C for 1 h.
11|
Transfer each well of the transformed bacterial cultures to a well of a 96-well deep-well plate containing 1.1 ml of 2× YT medium with 100 µg/ml carbenicillin (or ampicillin). Incubate the plate at 37 °C with orbital shaking at 200 r.p.m. for 24 h. 13| Using a reagent trough and a multichannel pipette, distribute 9.2 µl per well of the PCR master mix from
Step 12 into thin-walled 96-well PCR microtiter plates.
14|
Using a multichannel pipette, add 0.8 µl of bacterial culture from Step 11 to each well as DNA template, for a final reaction volume of 10 µl. Seal the PCR plate using a heat sealer or aluminum foil.  crItIcal step Wells G12 and H12 are used as negative control (water as template) and positive control (10 ng of empty pDEST-AD), respectively.
15|
Carry out the PCR as follows. Set the lid temperature to 104 °C to prevent condensation of the sample on the plate seal. 16| If the PCR is successful, as determined by running a 0.8% agarose gel to observe the expected DNA sizes, prepare glycerol stock plates by combining 80 µl of sterile 40% (vol/vol) glycerol with 80 µl of bacterial culture in 96-well round-bottom plates. Mix well. Store the plates at -80 °C.  pause poInt Glycerol stocks can be stored at -80 °C indefinitely.
17|
For the remaining bacterial culture in 96-well deep-well plates, perform miniprep plasmid isolation using a Qiagen 96-well plasmid extraction kit, using a bench-vacuum setting or a Qiagen liquid-handling robot, according to the manufacturer's instructions. Measure DNA concentration by a high-throughput NanoDrop 8000 spectrophotometer. A concentration >30 ng/µl is expected to continue to the next step.
High-throughput generation of Dna fragments flanking the mutation site • tIMInG 4 h 18| Dilute the wild-type pDEST-AD plasmids with ddH 2 O at a ratio of 1:50 to use as PCR template.
19|
To amplify the 5′ fragment, prepare a PCR master mix with all components except the reverse primer and the template, as detailed below. Generate enough mixture for all reactions, plus an additional 10% to allow for loss during pipetting steps.  crItIcal step The use of a hot-start polymerase allows one to do all the PCR setup at room temperature rather than on ice, which is cumbersome when dealing with multiple plates of PCR reactions. The use of a proofreading enzyme such as KOD ensures high-fidelity amplification.
20|
To amplify the 3 fragment, prepare a PCR master mix with all components except the forward primer and the template, as detailed below. Generate enough mixture for all reactions, plus an additional 10% to allow for loss during pipetting steps. 21| Using a reagent trough and a multichannel pipette, distribute 6 µl of the PCR master mixes per well into thin-walled 96-well PCR microtiter plates.
22| Using a multichannel pipette or a liquid-handling robot, add 2 µl of diluted wild-type pAD-gene template and 2 µl of mutation reverse primer from Step 2 to the distributed 5 fragment PCR master mix or 2 µl of mutation forward primer from
Step 2 to the distributed 3 fragment PCR master mix, for a final reaction volume of 10 µl and a final primer concentration of 0.1 µM for each primer. Seal the PCR plate using a heat sealer or aluminum foil. 23| Carry out the PCRs as follows. Set the lid temperature to 104 °C to prevent condensation of the sample on the plate seal. High-throughput mutagenesis of cancer variants by fusion pcr • tIMInG 4 h 25| Add 2-3 µl each of the 5′ and 3′ fragment PCR products generated in Step 23 to the same 100 µl of ddH 2 O to serve as fusion PCR templates.  crItIcal step These templates should be prepared right before performing fusion PCR.
26|
Fusion PCR: generate a PCR master mix for the fusion PCR, containing all components except template, as described below. Generate enough mixture for all reactions, plus an additional 10% to allow for loss during pipetting steps.  crItIcal step The use of a hot-start polymerase allows one to do all the PCR setup at room temperature rather than on ice, which is cumbersome when dealing with multiple plates of PCR reactions. The use of a proofreading enzyme such as KOD ensures high-fidelity amplification.
27| Using a reagent trough and a multichannel pipette, distribute 18 µl of the PCR master mix per well into thin-walled 96-well PCR microtiter plates.
28| Using a multichannel pipette or a liquid-handling robot, add 2 µl of the diluted fusion PCR template generated in Step 25 to the distributed PCR master mix, for a final reaction volume of 20 µl. Seal the PCR plate using a heat sealer or aluminum foil. 
29|
32| Repeat
Step 7, using 2 µl per well of mutation fusion PCR products from Step 30. Then repeat Step 8 using 1 µl of Gateway BP reaction products from Step 31, followed by repeating Steps 9 and 10.
33| To obtain single colonies, spot 5 µl of the transformed bacterial culture onto a 15-cm LB agar plate containing 100 µg/ml spectinomycin. Incubate the plate at 37 °C with orbital shaking at 200 r.p.m. for 24 h.  crItIcal step To ensure that single colonies rather than a patch are obtained, it is better to also perform serial dilutions of the transformed bacterial culture with H 2 O (such as 1:10) and then spot 5 µl onto a 15-cm LB + spectinomycin agar plate.
34|
Verify the identity of BP reaction products by bacterial PCR by repeating Steps 12-16, using M13F and M13R primers in Step 12, and 10 ng of empty pDONR223 as positive control in Step 14.
? troublesHootInG Verification of mutation entry clones by barcoded next-generation sequencing • tIMInG 5-6 d hands-on, 2-3 weeks' expansion  crItIcal All mutation entry clones must be verified, usually by barcoded pooling and next-generation sequencing technologies. Note that if only a few mutant clones must be confirmed, traditional Sanger sequencing with walking primers 56 may be more cost-effective, and can be used to sequence the PCR products generated in Step 34.
35|
Make pools of ~1,000 PCR products by transferring all PCR products from each well of 96-well plates to a common reservoir, and mixing well by gentle shaking or pipetting. 
ppI validation by transfer of mutant entry clones into Gpca vectors by Gateway lr reactions • tIMInG 2-3 d 81|
Perform LR reactions to transfer cancer mutation entry clones into GPCA vectors by repeating Steps 6-11, instead using pSPICA-C1 or pSPICA-N2 vectors in Step 6, and using 2 µl of cancer mutation entry clone plasmids (50-100 ng/µl) from
Step 41 per well in Step 7.
82| Verify the identity of LR reaction products by repeating Steps 12-16, instead using pCiNeo-Univ and pCiNeo-Rev as primers in Step 12, and empty pSPICA-C1 or pSPICA-N2 vector as a control in Step 14. Then follow Step 17 for plasmid extraction.
? troublesHootInG cell culture and Dna cotransfection using peI • tIMInG 2-3 d 83| Grow HEK 293T cells in DMEM (DMEM-GlutaMAX), supplemented with 10% (vol/vol) FCS, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37 °C with 5% CO 2 .
84| Seed 100 µl per well at a concentration of 3.0 × 10 4 cells per well into a desired number of 96-well plates. Incubate the plates overnight at 37 °C with 5% CO 2 .
85| Prepare 100 ng of DNA per construct (pSPICA-C1 and pSPICA-N2, each fused in frame with tested protein pairs) for transfection. Add DMEM (serum-and antibiotic-free) to a final volume of 36 µl.
86|
For every 100 samples in a 96-well plate, prepare PEI solution by adding 225 µl of 1 mg/ml PEI (stock solution, pH=7.0) to 3 ml of DMEM (serum-and antibiotic-free). Mix well. Remember to make an extra 10-15% volume to account for the medium loss during pipetting, especially when using automated robotics. 
87|
91|
Prepare the Renilla luciferase substrate reagent (Renilla luciferase assay system) using the specified buffer solution. Mix well. Add 50 µl of substrate to each well (handle only one plate at a time).
92|
Immediately measure the luciferase enzymatic activity by a luminescence microplate reader (Fig. 5) . The Renilla luminescence counting program has an integration time of 10 s after injection of 50 µl of luciferase substrate reagent.
Gpca interaction scoring and data analysis • tIMInG 1 d 93| For each tested protein pair, X-Y, data normalization is performed by dividing the luminescence unit of cells cotransfected with pSPICA-C1-X and pSPICA-N2-Y by the luminescence control unit either from cells cotransfected with pSPICA-C1-X and empty pSPICA-N2 vector, or from cells cotransfected with pSPICA-N2-Y and empty pSPICA-C1 vector.
94|
The interaction score is defined as the mean of the log2 of the two normalized luminescence values.
95|
Titrate the 'threshold' signal of quantitative outputs to an acceptable range. Set the threshold such that any pair scoring above that threshold is considered 'positive' and any pair scoring otherwise is considered 'negative' . The recovery rate of false-positive pairs is restricted to 1-2.5%.
? troublesHootInG Troubleshooting advice can be found in table 2. 
